# Alnylam Pharmaceuticals, Inc.  Share Price Target ‘$222.41’, now 50.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/alnylam-pharmaceuticals-inc.share-price-target-222.41-now-50.9-upside-potential/4121154290
- Published: 2024-05-01T14:29:35+01:00
- Author: Charlotte Edwards

**Alnylam Pharmaceuticals, Inc.** with ticker code (ALNY) now have 22 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The range
between the high target price and low target price is between $395.00 and $136.00
calculating the mean target share price we have $222.41. (at the time of writing).
Given that the stocks previous close was at $147.36 this indicates there is a potential
upside of 50.9%. The 50 day MA is $150.11 while the 200 day moving average is $172.21.
The market capitalization for the company is 18.20B. The stock price for the company
is currently is currently $143.95 USD

 The potential market cap would be $27,473,378,346 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $14.64 and
a -4.78% return on assets.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The
Company is engaged in developing therapeutics based on ribonucleic acid interference(
RNAi). Its pipeline includes five marketed products and over ten clinical programs,
including several in late-stage development, across four strategic therapeutic areas(
STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases,
and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), 
AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran).
ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin
amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase
1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease
manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting
hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.

Share on: